Lozano, R.; Lorente, D.; Aragon, I.M.; Romero-Laorden, N.; Nombela, P.; Mateo, J.; Reid, A.H.M.; Cendón, Y.; Bianchini, D.; Llacer, C.;
et al. Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients. Cancers 2021, 13, 2334.
https://doi.org/10.3390/cancers13102334
AMA Style
Lozano R, Lorente D, Aragon IM, Romero-Laorden N, Nombela P, Mateo J, Reid AHM, Cendón Y, Bianchini D, Llacer C,
et al. Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients. Cancers. 2021; 13(10):2334.
https://doi.org/10.3390/cancers13102334
Chicago/Turabian Style
Lozano, Rebeca, David Lorente, Isabel M. Aragon, Nuria Romero-Laorden, Paz Nombela, Joaquim Mateo, Alison H. M. Reid, Ylenia Cendón, Diletta Bianchini, Casilda Llacer,
and et al. 2021. "Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients" Cancers 13, no. 10: 2334.
https://doi.org/10.3390/cancers13102334
APA Style
Lozano, R., Lorente, D., Aragon, I. M., Romero-Laorden, N., Nombela, P., Mateo, J., Reid, A. H. M., Cendón, Y., Bianchini, D., Llacer, C., Sandhu, S. K., Sharp, A., Rescigno, P., Garcés, T., Pacheco, M. I., Flohr, P., Massard, C., López-Casas, P. P., Castro, E.,
... Olmos, D.
(2021). Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients. Cancers, 13(10), 2334.
https://doi.org/10.3390/cancers13102334
